Search Results - "Kates, RE"

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial by Hofmann, Daniel, Nitz, Ulrike, Gluz, Oleg, Kates, Ronald E, Schinkoethe, Timo, Staib, Peter, Harbeck, Nadia

“…Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic single molecular markers or genomic signatures is a therapeutic…”
Get full text

Abstract P2-07-01: Association of TILs with clinical parameters, recurrence score, and prognosis in patients with early HER2-negative breast cancer (BC) – A translational analysis of the prospective WSG planB trial by Liedtke, C, Gluz, O, Heinisch, F, Feuerhake, F, Kreipe, HH, Clemens, M, Nuding, B, Kraemer, S, Reimer, T, Svedman, C, Shak, S, Nitz, U, Kates, RE, Harbeck, N, Christgen, M

“…Abstract Introduction: Tumor-infiltrating lymphocytes (TILs) have been associated with prognosis and with chemotherapy response among patients with BC,…”
Get full text

Abstract OT3-3-02: ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer by Gluz, O, Hofmann, D, Kates, RE, Harbeck, N, Nitz, U

“…Abstract Background: Appropriate indication for chemotherapy (CTx) in patients with hormone receptor (HR) positive breast cancer (BC), prediction of CTx…”
Get full text

Abstract S6-07: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial by Gluz, O, Nitz, U, Liedtke, C, Christgen, M, Sotlar, K, Grischke, EM, Forstbauer, H, Braun, M, Warm, M, Hackmann, J, Uleer, C, Aktas, B, Schumacher, C, Bangemann, N, Lindner, C, Kuemmel, S, Clemens, M, Potenberg, J, Staib, P, Kohls, A, Pelz, E, Kates, RE, Wuerstlein, R, Kreipe, HH, Harbeck, N

“…Abstract Background: Pathological complete response (pCR) is associated with improved prognosis in TNBC, but optimal chemotherapy remains unclear. Use of…”
Get full text

Abstract P5-07-03: Prosigna® results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study by Wuerstlein, R, Sotlar, K, Gluz, O, Hofmann, D, Otremba, B, Von Schumann, R, Witzel, I, Schindlbeck, C, Janni, W, Schem, C, Bauerfeind, I, Hasmueller, S, Tesch, H, Paulenz, A, Morel, P, Cowens, W, Hornberger, J, Kates, RE, Pelz, E, Harbeck, N

“…Abstract Background: Prosigna is a standardized test measuring expression levels of 50 classifier genes (PAM50) in breast tumor tissue using nCounter®…”
Get full text

Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer by Harbeck, N, Gluz, O, Christgen, M, Braun, M, Kuemmel, S, Schumacher, C, Potenberg, J, Kraemer, S, Kleine-Tebbe, A, Augustin, D, Aktas, B, Forstbauer, H, Tio, J, Liedtke, C, Kates, RE, Wuerstlein, R, de Haas, SL, Kiermaier, A, Kreipe, HH, Nitz, U

“…Abstract Background: In HER2+ early breast cancer (eBC) pCR rates after standard neoadjuvant chemo- + anti-HER2 therapy differ according to hormone-receptor…”
Get full text

Abstract P1-13-01: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial by Gluz, O, Nitz, U, Liedtke, C, Christgen, M, Sotlar, K, Grischke, EM, Forstbauer, H, Braun, M, Warm, M, Hackmann, J, Uleer, C, Aktas, B, Schumacher, C, Bangemann, N, Lindner, C, Kuemmel, S, Clemens, M, Potenberg, J, Staib, P, Kohls, A, Pelz, E, Kates, RE, Wuerstlein, R, Kreipe, HH, Harbeck, N

“…Abstract Background: Pathological complete response (pCR) is associated with improved prognosis in TNBC, but optimal chemotherapy remains unclear. Use of…”
Get full text

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination by HARBECK, Nadia, KATES, Ronald E, SCHMITT, Manfred

“…A strong prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor and plasminogen activator inhibitor type 1 (PAI-1) as individual…”
Get full text

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) by HARBECK, Nadia, KATES, Ronald E, LOOK, Maxime P, MEIJER-VAN GELDER, Marion E, KLIJN, Jan G. M, KRÜGER, Achim, KIECHLE, Marion, JÄNICKE, Fritz, SCHMITT, Manfred, FOEKENS, John A

“…Risk assessment and prediction of response to treatment are prerequisites for individualized adjuvant therapy decisions in breast cancer. The strong prognostic…”
Get full text

Abstract P2-10-08: Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial by Gluz, O, Kreipe, HH, Kates, RE, Christgen, M, Liedtke, C, Shak, S, Clemens, M, Salem, M, Liedtke, B, Aktas, B, Markmann, S, Uleer, C, Augustin, D, Thomssen, C, Nitz, U, Harbeck, N

“…Abstract Background: Routine use of multigene RT-PCR based assays as Recurrence Score (RS) vs. single markers (grade, uPA/PAI-1, HR, HER2, Ki-67) is…”
Get full text

Abstract P6-05-11: Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine by Harbeck, N, Gluz, O, Kreipe, HH, Christgen, M, Svedman, C, Shak, S, Hofmann, D, Kuemmel, S, Nuding, B, Rezai, M, Schumacher, C, Kusche, M, Forstbauer, H, Maass, N, Kraemer, S, Aktas, B, Mohrmann, S, Wuerstlein, R, Kates, RE, Nitz, U

“…Abstract Background: Despite promising evidence regarding outcome prediction, endocrine sensitivity, as determined by proliferation response to short-term…”
Get full text

Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast Cancer by ZEMZOUM, Iris, KATES, Ronald E, HARBECK, Nadia, ROSS, Jeffrey S, DETTMAR, Peer, DUTTA, Moshumi, HENRICHS, Cordula, YURDSEVEN, Suna, HÖFLER, Heinz, KIECHLE, Marion, SCHMITT, Manfred

“…The independent clinical relevance of invasion factors urokinase-type plasminogen activator (uPA)/PAI-1 and HER2 status was evaluated in lymph node-negative…”
Get full text

Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, D, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy by HARBECK, Nadia, ALT, Uta, BERGER, Ursula, KRÜGER, Achim, THOMSSEN, Christoph, JÄNICKE, Fritz, HÖFLER, Heinz, KATES, Ronald E, SCHMITT, Manfred

“…Purpose : Prognostic and predictive impact of five proteolytic factors associated with tumor invasion and metastasis in primary breast cancer were evaluated…”
Get full text

Abstract P4-06-22: Persistent Triple-Negative Phenotype Is Associated with Poorest Outcome among Patients with Metastatic Breast Cancer (BC) - Results of the Retrospective Multicenter PriMet Study Comparing Molecular BC Phenotypes in Primary Tumors and Corresponding Recurrences by Liedtke, C, Gluz, O, Heitz, F, Freudenberger, M, Würstlein, R, Hungermann, D, Ortmann, M, Kates, RE, Nitz, U, du Bois, A, Fehm, TN, Harbeck, N.

“…Abstract Background: Patients with triple negative (TN) breast cancer (BC), defined by lack of both ER/PR expression and HER2 overexpression, have an…”
Get full text

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse by HARBECK, N, THOMSSEN, C, BERGER, U, ULM, K, KATES, R. E, HÖFLER, H, JÄNICKE, F, GRAEFF, H, SCHMITT, M

“…In 1991, our group was the first to report the prognostic strength of plasminogen activator inhibitor type 1 (PAI-1) in primary breast cancer. The prognostic…”
Get full text

Androgenrezeptor (AR) und Forkhead BoxA1 (FOXA1) als Prognosefaktoren beim frühen HER2-negativen Mammakarzinom – eine translationale Substudie im Rahmen der prospektiven Phase-III-WSG-Plan B Studie by Degenhardt, T, Kreipe, HH, Gluz, O, Kates, RE, Liedtke, C, Kraemer, S, Clemens, MR, Nuding, B, Reimer, T, Aktas, B, Kuemmel, S, Just, M, Lorenz-Salehi, F, Uleer, C, Stefek, A, Heyl, V, Würstlein, R, Nitz, U, Christgen, M, Harbeck, N

“…Abstract only…”
Get full text

WSG-BCIST mit PAM50 – Prospektive Beobachtungsstudie des klinischen Outcomes für den Prosigna® Technologie Breast Cancer Intrinsic Subtype Test by Würstlein, R, Harbeck, N, Sotlar, K, Pelz, E, Otremba, B, Witzel, I, Janni, W, Schindlbeck, C, Schem, C, Tesch, H, Hofmann, D, Kates, RE, Gluz, O

“…Abstract only…”
Get full text

Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma by Haas, D W, Clough, L A, Johnson, B W, Harris, V L, Spearman, P, Wilkinson, G R, Fletcher, C V, Fiscus, S, Raffanti, S, Donlon, R, McKinsey, J, Nicotera, J, Schmidt, D, Shoup, R E, Kates, R E, Lloyd, Jr, R M, Larder, B

“…Defining the source of HIV-1 RNA in cerebrospinal fluid (CSF) will facilitate studies of treatment efficacy in the brain. Four antiretroviral drug-naive adults…”
Get more information

Clinical pharmacokinetics of amiodarone by LATINI, R, TOGNONI, G, KATES, R. E

“…Amiodarone is an iodinated benzofuran derivative with recognised antiarrhythmic activity in man. As yet, its pharmacokinetic behaviour has not been…”
Get full text

Effect of High-Dose Oral Ganciclovir on Didanosine Disposition in Human Immunodeficiency Virus (HIV)-Positive Patients by Jung, Donald, Griffy, Kay, Dorr, Albert, Raschke, Robert, Tarnowski, Thomas L., Hulse, James, Kates, Robert E.

“…This study was designed to investigate the interaction between high‐dose oral ganciclovir (6,000 mg/day) and didanosine at steady state in patients who were…”
Get full text